A GLP-1 prescribing framework is only as strong as the evidence sitting behind each decision point in it. The trial data supports clear eligibility thresholds, structured titration, planned review intervals and defined stopping criteria. It does not support open ended prescribing, escalation without review, or applying a framework written for one population to everyone. Reading one critically means asking, at every step, which study it came from and which patients that study recruited.
What this article covers
- Why the population a trial recruited matters more than its headline result
- The four decision points every prescribing framework has to justify
- How to tell a framework built on evidence from one built on convention
- Where monitoring intervals come from, and what a real stopping rule looks like
Why does the trial population matter more than the headline result?
When a new agent reports results, attention lands on the average change in body weight. For a practitioner writing a framework that is the least useful number in the paper. Who was recruited matters far more. Cohorts in this area have typically been adults meeting specific body mass index thresholds, often with a weight related comorbidity, screened to exclude conditions including a personal or family history of medullary thyroid carcinoma, prior pancreatitis, severe gastrointestinal disease and pregnancy. If your framework says nothing about how those exclusions map onto your own screening, you have imported the headline result without the conditions that produced it.
This is where private practice frameworks quietly drift. A patient sitting slightly below the trial threshold, or with a comorbidity that was an exclusion rather than an inclusion, is not automatically unsuitable. But treating them is a clinical judgement made outside the evidence base and needs recording as such. The GLP-1 Agonists and Weight Management course dwells on that distinction, because it is where a defensible service and an indefensible one separate.
A related habit worth breaking is treating all agents in the class as interchangeable because they share a mechanism. Receptor selectivity differs, and the licensed indications and titration schedules are not the same. A framework that says “GLP-1 therapy” without naming which agent and which schedule is not really a framework. Current summaries of product characteristics are the primary reference, and the MHRA governs how those products may be discussed.
Which four decision points does every framework have to justify?
Strip a prescribing framework back and it makes four claims: this patient is eligible, this is the starting point and escalation path, these are the review intervals, this is when treatment stops. Each needs a source. If you cannot name it, you are working from convention.
Write them down separately, because each fails differently. Eligibility failures surface as complaints, titration failures as dropouts, review failures in an audit, and missing stopping rules as patients treated for a very long time with no documented reason why. Our Medical Weight Loss Mastery course builds the framework around these four points so each can be evidenced independently.
How can you tell an evidence based framework from a conventional one?
Convention is not always wrong. Plenty of it encodes sensible practice that predates the trial which would have confirmed it. The problem is that convention cannot be defended when challenged, and cannot be updated when the evidence moves, because nobody knows what it was resting on. The test is simple: pick any threshold or interval and ask where the number came from.
| Element of the framework | The question to ask | What a weak answer looks like |
|---|---|---|
| Eligibility threshold | Which trial or guideline set this number, and did it recruit patients like mine? | It is the number everyone uses |
| Titration interval | Does this match the licensed schedule for this specific agent? | We shortened it because patients were impatient |
| Monitoring frequency | What is being monitored at this visit, and what would change as a result? | Monthly, because that is when they come in |
| Response threshold | When is a non response declared, and measured how? | We review it as we go |
| Stopping criteria | What ends treatment, on safety and efficacy grounds? | The framework does not say |
| Escalation out of service | Which findings trigger referral, and to whom? | Case by case |
Where the economics of the service come into it, the useful framing is what drives the cost of safe delivery rather than any figure: monitoring intensity, frequency of clinical contact, practitioner time spent on structured review, and course length. A framework with thin monitoring is cheaper to run and much harder to defend. Make that trade off consciously and write it down, rather than letting it emerge as a clinic gets busier.
Where do monitoring intervals actually come from?
Monitoring intervals in the trial literature are tied to the endpoints being measured, which is why they rarely transfer neatly into a clinic. Your service is not measuring an endpoint, it is managing a patient, so the interval needs justifying on clinical grounds: frequent while escalation and tolerability are in play, less frequent once a patient is established, with a longer interval review that reassesses the whole rationale rather than the numbers.
What makes an interval arbitrary is not its length but the absence of any statement about what happens at it. “Review at four weeks” produces appointments that record a weight and nothing else. “At four weeks assess gastrointestinal tolerability, adherence to the titration schedule, hydration, and whether escalation is appropriate” produces a record that stands up. That is a documentation point as much as a clinical one, and it runs through how a service handles structured consultation and review across the pathway.
National guidance on overweight and obesity management in adults from NICE remains the reference point for the broader pathway that pharmacological treatment sits inside. Read it for the surrounding expectations about assessment, multidisciplinary input and review, because those shape what a reasonable practitioner is assumed to have done.
Appraising a framework before you adopt it
- Every threshold in it can be traced to a named guideline or trial
- It names specific agents and their licensed titration schedules rather than the class
- Each review interval states what is assessed and what would change as a result
- It contains an explicit response threshold and an explicit stopping rule
- It describes how patients outside the studied population are handled and recorded
- It states which findings trigger referral out of the service
Why is the stopping rule the part that gets left out?
Because it is uncomfortable. A stopping rule means telling a patient who wants to continue that treatment is ending, and accepting that some patients will not respond sufficiently to justify continued pharmacological treatment. Frameworks written to keep a service running tend to lack one. Frameworks written to be defensible always have one.
A workable rule has three limbs. Safety: the adverse effects and findings that end treatment immediately. Efficacy: the response threshold and when it is assessed. Governance: situations where treatment stops because the patient cannot be reviewed, has become uncontactable, or is obtaining supply elsewhere in parallel. Practitioners usually discover they need that third limb after the fact.
Writing it down also protects you in the harder conversation, because the rule was set and explained at the start of treatment rather than introduced when it becomes unwelcome. Patients accept a rule far more readily than a decision that appears to have been made about them. That is a communication skill as much as a clinical one, and it is taught alongside the framework on our weight loss courses.
Frequently asked questions
Does a framework have to be written down to be defensible?
How often should a prescribing framework be reviewed?
Is it acceptable to treat a patient who falls outside the trial population?
How do you assess response without relying on weight alone?
Where should the framework live in the clinical record?
Building a framework you can defend
A prescribing framework is not paperwork. It is the record of your clinical reasoning, written down before you need it, and it is what stands between a difficult outcome and an indefensible one.
Our CPD-accredited courses are taught by two practising pharmacists who write and revise these frameworks in their own clinical work. If you want to build one properly, or stress test the one you already use, we are contactable before, during and after training.
